Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04604132
Title	Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03)
Acronym	FIDES-03
Recruitment	Terminated
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Basilea Pharmaceutica
Indications	gastroesophageal junction adenocarcinoma gastric adenocarcinoma
Therapies	Atezolizumab + Derazantinib Derazantinib + Paclitaxel + Ramucirumab Derazantinib Paclitaxel + Ramucirumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS \| ARG